Lipid Profiles and Lipid-Lowering Therapy at the Time of Acute Myocardial Infarction
Authors' conclusion
In a contemporary AMI cohort, ∼2 in 3 patients presenting with a new ASCVD diagnosis were not previously on a statin, and nearly all had LDL-C ≥55 mg/dL. Among AMI patients with known ASCVD, ∼1 in 4 were not on a statin, and ∼4 in 5 had LDL ≥55 mg/dL. Combination LLT remained low at presentation and discharge despite suboptimal LDL-C, underscoring actionable gaps in ASCVD management.
Study context
- Population
- Patients hospitalized with acute myocardial infarction (AMI) from March 2018 to August 2022
- Participants
- 1,159 vs 689
- Exposure
- No prior atherosclerotic cardiovascular disease (ASCVD) diagnosis vs Prior ASCVD
- No prior ASCVD diagnosisn = 1,159
- Prior ASCVDn = 689
- Outcome
- LDL-C levels and LLT use at presentation
- Follow-up
- Prior to admission
Main finding
As reported in the abstract
LDL-C ≥55 mg/dL
LDL-C ≥70 mg/dL
| Outcome | No prior ASCVD diagnosis | Prior ASCVD |
|---|---|---|
| On outpatient statin therapy | 33.6% | — not stated in the abstract |
| Previously on statins | — not stated in the abstract | 73.7% |
| On combination LLT | — not stated in the abstract | 3.9% |
— not stated in the abstract
Observational data: associations, not effects.
Further findings
Statin eligibility in the 2026 U.S. dyslipidemia guideline (no prior ASCVD, not taking LLT, aged 18 to 79 years with available risk data)
- Met statin eligibility
- 89.0%
LLT at discharge, all AMI patients
- Discharged on statins
- 94.0%
- With high intensity (of those discharged on statins)
- 81.8%
- Discharged with combination LLT
- 5.0%
LLT intensification at discharge (prior ASCVD and low-density lipoprotein cholesterol (LDL-C) ≥55 mg/dL)
- Increase in statin intensity
- 24.9%
- Received combination LLT
- 7.2%
- No LLT intensification
- 47.0%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →